Restless Legs Syndrome Epidemiology Forecast 2025-2034

In the United States, about 10% of the population is affected by restless legs syndrome. It is reported to be more prevalent among women with middle-aged individuals more likely to experience severe symptoms. Approximately 2% of school-age children are also estimated to have restless leg syndrome.

Restless Legs Syndrome Epidemiology Forecast Report Coverage

The “Restless Legs Syndrome Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of restless legs syndrome. It projects the future incidence and prevalence rates of restless legs syndrome across various populations. The study covers age and type as major determinants of the restless legs syndrome-affected population. The report highlights patterns in the prevalence of restless legs syndrome over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of restless legs syndrome in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Restless Legs Syndrome: Disease Overview

Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is a neurological disorder in which the affected individual experiences an uncontrollable urge to move the legs. The symptoms are observed to be worse during periods of rest or inactivity, especially in the evening and night. Low iron levels, dopamine dysfunction, a family history of RLS, and certain chronic conditions (such as kidney disease, diabetes, Parkinson’s disease, and peripheral neuropathy) can increase the risk of restless legs syndrome.

Restless Legs Syndrome: Treatment Overview

Lifestyle changes such as maintaining a consistent sleep schedule, creating a relaxing bedtime routine, and ensuring the sleep environment is comfortable can help in reducing the symptoms of restless legs syndrome. In case of iron deficiency (even if blood iron is normal but brain iron is insufficient), iron supplements are prescribed. Dopamine agonists like Pramipexole (Mirapex), Ropinirole (Requip), and Rotigotine (Neupro) are used to mimic the effects of dopamine in the brain, thereby helping in managing the symptoms.

Epidemiology

The Restless Legs Syndrome epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for Restless Legs Syndrome by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for restless legs syndrome and their trends. The data is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• It is estimated that 5% to 15% of the population may be affected by restless legs syndrome, with familial restless legs syndrome likely to develop at ages younger than 45.
• Restless legs syndrome is reported to be common among women and white people, with the risk of the disease advancing as people get older.
• Studies show that restless legs syndrome is rare in children, with approximately 2% of school-age children affected by the condition.
• Restless legs syndrome affects 11% to 29% of pregnant women, occurring three times more frequently in pregnant women compared to nonpregnant women. The condition is most prevalent during the third trimester of pregnancy.

Country-wise Restless Legs Syndrome Epidemiology

The restless legs syndrome epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of restless legs syndrome varies significantly between countries due to differences in genetic factors, diet and lifestyle, healthcare access, environmental influences (such as pollution or stress), and socioeconomic factors (like income levels and work-related stress). In the United States, it is estimated that about 7% to 10% of individuals have restless legs syndrome, with roughly 2% to 3% experiencing moderate to severe symptoms.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of restless legs syndrome based on several factors.
• The Restless Legs Syndrome Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population, and the unmet needs of the restless legs syndrome are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of restless legs syndrome epidemiology in the 8 major markets?
• What will be the total number of patients with restless legs syndrome across the 8 major markets during the forecast period?
• What was the country-wise prevalence of restless legs syndrome in the 8 major markets in the historical period?
• Which country will have the highest number of restless legs syndrome patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of restless legs syndrome during the forecast period of 2025-2034?
• What are the currently available treatments for restless legs syndrome?
• What are the disease risks, signs, symptoms, and unmet needs of restless legs syndrome?

This product will be delivered within 3-5 business days.